Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
Hamilton Health Sciences - Juravinski Hospital Cancer Centre, Hamilton, Ontario, Canada.
Eur J Haematol. 2022 Jul;109(1):3-9. doi: 10.1111/ejh.13774. Epub 2022 Apr 29.
Patient-reported outcome measures (PROMs), which are measures of symptom burden, health-related quality of life (HRQoL), and therapy effectiveness have become increasingly important in clinical research. They are unique in that they are reported directly from the patient, without clinician interpretation, thereby avoiding clinician bias. With an increased focus on the patient at the center of health care, PROMs have been increasingly incorporated into clinical research, systematic reviews, and clinical guidelines. Despite the recognition of the importance of including PROMs into clinical haematologic cancer research, barriers have prevented their integration into cancer research. This review highlights the value of including PROMs into clinical haematologic cancer research and addresses the methodological challenges in using and evaluating PROMs. We propose important questions for the malignant haematologist to consider when designing or evaluating a study that includes PROMs.
患者报告的结局指标（PROMs）是衡量症状负担、健康相关生活质量（HRQoL）和治疗效果的指标，在临床研究中变得越来越重要。它们的独特之处在于，它们是由患者直接报告的，无需临床医生解释，从而避免了临床医生的偏见。随着人们越来越关注医疗保健的中心是患者，PROMs 已经越来越多地被纳入临床研究、系统评价和临床指南。尽管已经认识到将 PROMs 纳入临床血液学癌症研究的重要性，但障碍阻止了它们在癌症研究中的整合。本综述强调了将 PROMs 纳入临床血液学癌症研究的价值，并解决了使用和评估 PROMs 时的方法学挑战。我们提出了恶性血液病学家在设计或评估包含 PROMs 的研究时需要考虑的重要问题。
